100,000 Shares in Kestra Medical Technologies, Ltd. $KMTS Purchased by Seven Grand Managers LLC

Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $2,652,000. Seven Grand Managers LLC owned approximately 0.17% of Kestra Medical Technologies as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Alliancebernstein L.P. raised its holdings in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after acquiring an additional 179,885 shares in the last quarter. Millennium Management LLC bought a new stake in Kestra Medical Technologies during the first quarter worth about $11,036,000. Geode Capital Management LLC raised its holdings in Kestra Medical Technologies by 26.5% during the fourth quarter. Geode Capital Management LLC now owns 419,115 shares of the company’s stock worth $11,117,000 after acquiring an additional 87,753 shares in the last quarter. UBS Group AG raised its holdings in Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after acquiring an additional 69,908 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after acquiring an additional 28,573 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on KMTS. BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. The Goldman Sachs Group dropped their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $27.40.

Kestra Medical Technologies Price Performance

NASDAQ:KMTS opened at $21.00 on Thursday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average price is $20.65 and its two-hundred day moving average price is $23.58. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.30 and a beta of 0.82. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business’s revenue for the quarter was up 62.7% on a year-over-year basis. On average, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Insider Transactions at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the transaction, the insider owned 334,786 shares in the company, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 45,000 shares of company stock valued at $919,050 in the last 90 days. 3.60% of the stock is owned by corporate insiders.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.